Registry tracking treatment and health of people with myeloma and amyloidosis
Collects information, blood samples and bone marrow tissue from adults with plasma cell diseases.
Plain-language title generated from the registry record
Registry title: Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Key facts
- Where
- Columbus, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have been diagnosed with a plasma cell disease, such as multiple myeloma or amyloidosis. It collects information and samples for research.
- Age
- 18 years and older
- Sex
- Women and men can join.
- Disease stage
- A diagnosis of a plasma cell dyscrasia (a disease of the plasma cells).
Main reasons for not taking part
- Prisoners cannot join.
Read by machine on 9 November 2026.
Where in United States
- Ohio State University Medical CenterColumbus, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ohio State University Comprehensive Cancer Center
- Trial code
- NCT01408225
- Record updated
- 23 March 2026
- Original description
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:Read full original descriptionShow less
Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis
The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:
* Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live. * Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups. * Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.
Inclusion:; Diagnosis of a plasma cell dyscrasia; Exclusion:; Prisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.